Immuneering Enterprise Value Over E B I T D A from 2010 to 2024
| IMRX Stock | USD 2.09 0.04 1.88% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (2.65) | Current Value (2.78) | Quarterly Volatility 26.4883429 |
Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 3.5 M, Interest Income of 3.5 M or Depreciation And Amortization of 369.7 K, as well as many indicators such as Price To Sales Ratio of 207, Dividend Yield of 0.0 or PTB Ratio of 2.42. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
Immuneering | Enterprise Value Over E B I T D A |
Latest Immuneering Corp's Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Immuneering Corp over the last few years. It is Immuneering Corp's Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immuneering Corp's overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Immuneering Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (43.78) | |
| Coefficient Of Variation | (60.50) | |
| Mean Deviation | 23.66 | |
| Median | (61.53) | |
| Standard Deviation | 26.49 | |
| Sample Variance | 701.63 | |
| Range | 60.3599 | |
| R-Value | 0.83 | |
| Mean Square Error | 230.91 | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 4.94 | |
| Total Sum of Squares | 9,823 |
Immuneering Enterprise Value Over E B I T D A History
About Immuneering Corp Financial Statements
Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (2.65) | (2.78) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.